HCW starts Mustang Bio at buy; PT $7

H.C. Wainwright initiated coverage of Mustang Bio (NASDAQ:MBIO) with a “buy” rating and $7 price target. The stock closed at $2.89 on Aug. 12.

Analyst Joseph Pantginis writes that Mustang is developing multiple novel targeted approaches, including:

  • A gene-therapy like approach, MB-107, that consists of a hybrid therapy coupling ex vivo gene therapy with allogeneic cell therapy for X-linked severe combined immunodeficiency, an immunodeficiency disorder, devoid of a targeted therapy, in which the body produces very few T-cells and natural killer cells.
  • Multiple CAR-T candidates (MB-101-106) addressing several hard to treat cancers, such as relapsed/refractory acute myeloid leukemia (r/r AML), glioblastoma (GBM) and prostate cancer.
  • And an oncolytic virus candidate, C134 (MB-108), to be delivered intratumorally in GBM.

He said that currently, his valuation includes MB-107 and MB-102 because they are more advanced clinically; their validated mechanism of action; promising clinical data to date; if approved, these two therapies may capture a good share of the market; and approaching key catalysts, such as transferring the IND for MB-107 to Mustang from partner, St. Jude, by the end of 2019, and follow-up data of the MB-102 Phase 1 study in the fourth quarter of 2019.

Following the recent acceptance of MB-102’s IND, Mr. Pantginis said Mustang and partner, City of Hope, may initiate a multicenter Phase 1/2 clinical trial of MB-102 in r/r AML, blastic plasmacytoid dendritic cell neoplasm and high-risk myelodysplastic syndromes later this year.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.